EHA 2026 | Evolving treatment strategies and unmet needs in acute lymphoblastic leukemia
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses how the treatment landscape for acute lymphoblastic leukemia (ALL) is rapidly evolving with the integration of novel targeted therapies, including bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. Dr Luskin explores how frontline strategies for both Philadelphia chromosome-positive and -negative ALL are expected to shift toward less intensive chemotherapy and more personalized approaches, while also highlighting the ongoing unmet need for effective therapies in T-cell ALL. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
